AbbVie (NYSE:ABBV) has agreed to acquire all outstanding equity of neuroscience-focused biotech Aliada Therapeutics for $1.4B ...

The purchase of Aliada Therapeutics is “interesting for a number of reasons,” according to a Stifel analyst, one of which is ...

The transaction, seen as a vote of confidence, has put the focus on other drug firms testing similar barrier-bridging ...

The acquisition of Aliada Therapeutics will grant AbbVie access to a neuroscience-focused technology platform and an ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its ...

The acquisition will allow AbbVie to accelerate development of ALIA-1758, a potential disease-modifying therapy for Alzheimer ...

U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...

The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.

The acquisition of Aliada Therapeutics gives AbbVie access to a Phase I anti-amyloid antibody as well as the biotech’s novel ...

AbbVie (ABBV) to acquire Aliada Therapeutics for $1.4B in cash, enhancing focus on Alzheimer's disease with innovative ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier ...